Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655064 versus placebo in methotrexate-inadequate-response rheumatoid arthritis
NL-OMON40579Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of BI 655064 in rheumatoid arthritis (RA), sponsored by Boehringer Ingelheim. Primary endpoints: Safety and tolerability, Pharmacokinetics and 2 more. Started Apr 2014; status: active, not recruiting.
02
Drugs
BI 655064
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON40579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40579.